244 related articles for article (PubMed ID: 18791333)
21. [Hope for patients with rare diseases--"orphan" drugs].
Kuzelová M; Kubácková K; Palágyi M; Smíd M
Cas Lek Cesk; 2006; 145(4):296-300. PubMed ID: 16639930
[TBL] [Abstract][Full Text] [Related]
22. Comparative analysis of the scope of European Union paediatric investigation plans with corresponding orphan designations.
Ecker A; Mariz S; Naumann-Winter F; Norga K; Barisic I; Girard T; Tomasi P; Mentzer D; Sepodes B
Arch Dis Child; 2018 May; 103(5):427-430. PubMed ID: 29089318
[TBL] [Abstract][Full Text] [Related]
23. Rare diseases and orphan drugs.
Taruscio D; Capozzoli F; Frank C
Ann Ist Super Sanita; 2011; 47(1):83-93. PubMed ID: 21430345
[TBL] [Abstract][Full Text] [Related]
24. Rare diseases and orphan drugs: Latvian story.
Logviss K; Krievins D; Purvina S
Orphanet J Rare Dis; 2014 Sep; 9():147. PubMed ID: 25231378
[TBL] [Abstract][Full Text] [Related]
25. Drugs for rare disorders.
Cremers S; Aronson JK
Br J Clin Pharmacol; 2017 Aug; 83(8):1607-1613. PubMed ID: 28653488
[TBL] [Abstract][Full Text] [Related]
26. Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products.
Dear JW; Lilitkarntakul P; Webb DJ
Br J Clin Pharmacol; 2006 Sep; 62(3):264-71. PubMed ID: 16934041
[TBL] [Abstract][Full Text] [Related]
27. Orphan Medicines for Pediatric Use: A Focus on the European Union.
Bolislis WR; Corriol-Rohou S; Hill-Venning C; Hoogland H; Joos A; King D; Kitcatt V; Le Visage G; Kühler TC
Clin Ther; 2019 Dec; 41(12):2630-2642. PubMed ID: 31704041
[TBL] [Abstract][Full Text] [Related]
28. Economic considerations in the provision of treatments for rare diseases.
McCabe C; Edlin R; Round J
Adv Exp Med Biol; 2010; 686():211-22. PubMed ID: 20824448
[TBL] [Abstract][Full Text] [Related]
29. EU to review rare disease drugs market exclusivity.
Sheridan C
Nat Biotechnol; 2004 Sep; 22(9):1061. PubMed ID: 15340455
[No Abstract] [Full Text] [Related]
30. [The legal regulation of life cycle of orphan pharmaceuticals].
Gildeyeva GN; Kartavtsova TV
Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2014; (3):37-42. PubMed ID: 25219041
[TBL] [Abstract][Full Text] [Related]
31. A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation.
Pinxten W; Denier Y; Dooms M; Cassiman JJ; Dierickx K
J Med Ethics; 2012 Mar; 38(3):148-53. PubMed ID: 21947805
[TBL] [Abstract][Full Text] [Related]
32. Does orphan drug legislation really answer the needs of patients?
Haffner ME; Torrent-Farnell J; Maher PD
Lancet; 2008 Jun; 371(9629):2041-4. PubMed ID: 18555916
[No Abstract] [Full Text] [Related]
33. Review of 11 national policies for rare diseases in the context of key patient needs.
Dharssi S; Wong-Rieger D; Harold M; Terry S
Orphanet J Rare Dis; 2017 Mar; 12(1):63. PubMed ID: 28359278
[TBL] [Abstract][Full Text] [Related]
34. [Authorization and reimbursement of orphan drugs in an international comparison].
Roll K; Stargardt T; Schreyögg J
Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
[TBL] [Abstract][Full Text] [Related]
35. [Orphan drugs].
Kolár J; Chalabala M; Srámková H
Ceska Slov Farm; 2001 Mar; 50(2):59-65. PubMed ID: 11288591
[TBL] [Abstract][Full Text] [Related]
36. Developing treatments for inborn errors: incentives available to the clinician.
Haffner ME
Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
[TBL] [Abstract][Full Text] [Related]
37. The legal imperative for treating rare disorders.
Hyry HI; Roos JC; Manuel J; Cox TM
Orphanet J Rare Dis; 2013 Sep; 8():135. PubMed ID: 24010951
[TBL] [Abstract][Full Text] [Related]
38. Patient Access to Medicines for Rare Diseases in European Countries.
Detiček A; Locatelli I; Kos M
Value Health; 2018 May; 21(5):553-560. PubMed ID: 29753352
[TBL] [Abstract][Full Text] [Related]
39. Orphan drugs: the regulatory environment.
Franco P
Drug Discov Today; 2013 Feb; 18(3-4):163-72. PubMed ID: 22981668
[TBL] [Abstract][Full Text] [Related]
40. The European challenges of funding orphan medicinal products.
Szegedi M; Zelei T; Arickx F; Bucsics A; Cohn-Zanchetta E; Fürst J; Kamusheva M; Kawalec P; Petrova G; Slaby J; Stawowczyk E; Vocelka M; Zechmeister-Koss I; Kaló Z; Molnár MJ
Orphanet J Rare Dis; 2018 Nov; 13(1):184. PubMed ID: 30396361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
